Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: 0.31 + anemia + web  Related to the article below (Last Update: 8/4/2008)


Earthtimes (press release)
HFF, Inc. Reports Second Quarter 2008 Financial and Transaction ...
MarketWatch -
... 6403 ========== ========= ======== ========= Earnings per share - basic $ 0.06 $ 0.31 $ 0.01 $ 0.48 Earnings per share - diluted $ 0.06 $ 0.31 $ 0.01 ...
Health Management Associates, Inc. Reports Second Quarter Earnings WELT ONLINE
QIAGEN Reports Second Quarter 2008 Results and Increases Full Year ... CNNMoney.com (press release)
Luxottica Sees Strong Growth in Net Sales for 2Q08: +12.6% at ... PR Newswire (press release)
Genetic Engineering News (press release) - Trading Markets (press release)
all 871 news articles »  HMA - QGEN - OCR
Man had 0.31 alcohol level
Record-Searchlight, CA - Jul 31, 2008
Dr. Susan Comfort, Shasta County's forensic pathologist, said Justin Wigham had a 0.31 blood-alcohol concentration. It's illegal in California to drive with ...
Pakistan inflation surges by
SteelGuru, India - Aug 3, 2008
The inflation, however, recorded an increase of 0.31% over the previous week, indicating a rising trend in the prices of these commodities. ...
SPI based inflation up by 0.33%
Pakistan Daily Mail, Pakistan - Aug 2, 2008
The SPI for the combined group registered increase of 0.31 per cent by rising from 205.98 in the previous week to 206.61 in the week under review. ...
Elisa Q2 profits miss forecasts, repeats outlook
Reuters - Jul 31, 2008
Elisa posted April-June earnings per share of 0.20 euro, compared with 0.31 euro a year earlier, and missing all analysts' forecasts in a Reuters poll, ...
UPDATE 1-Weak mobile unit hits Finland's Elisa Q2 profits Reuters
all 7 news articles »
MDC Hldgs Inc (MDC) more shares bought by Bank Of America Corp
Mffais.com, CA - Aug 2, 2008
LONG BEACH (Mffais.com) - Bank Of America Corp added additional 430 (0.31 %) shares of MDC Hldgs Inc (MDC), bringing their current holdings to 136445 shares ...BAC

MSN Money UK
Average two-year fixed deals fall below 7%
Scotsman, United Kingdom - Aug 1, 2008
HSBC this week trimmed its two-year fixed deal by 0.31 per cent and reduced booking fees on fixed rate mortgages by ?200 to ?599. Abbey, which this week was ...
Two-Year Fixes Get Cheaper Find a Property
HSBC latest to cut mortgage rates Yorkshire Evening Post
all 22 news articles »
Hawaiian Electric Industries, Inc. Reports Solid Second Quarter ...
Trading Markets (press release), CA -
... Dividends per common share $ 0.31 $ 0.31 $ 0.62 $ 0.62 ========= ========= =========== =========== Weighted-average number of common shares outstanding ...HE
Mining shares weigh London stock market down
Xinhua, China - Aug 1, 2008
... was weighed down by mining stocks after metals prices fell on Friday, and by midday the FTSE 100 index was down 16.8 points at 5395.10, or 0.31 percent. ...
BNC Bancorp profits fall The Business Journal of the Greater Triad ...
Bizjournals.com, NC -
The ratio of non-performing assets to total assets rose from 0.31 percent to 0.89 percent. Montgomery said one large residential construction project was ...BNCN - KIDS
Source: Google News

… contractions and oropharyngeal and esophageal transits in patients with iron deficiency anemia -
ALM Miranda, RO Dantas - American Journal of Gastroenterology, 2003 - Blackwell Synergy
... 4) was longer in patients (0.31 ? 0.02 s) than ... the iron deficiency to progress to
web formation or ... conclusion, patients with iron deficiency anemia may have ...

Blue sclerae: a sign of iron deficiency anemia in children? -
M Beghetti, B Mermillod, DS Halperin - Pediatrics, 1993 - Am Acad Pediatrics
... http://www.pediatrics.org the World Wide Web at: The online version of ... all of which
usually become apparent when the anemia is profound and ... 0.31 0.67 0.71 0.90 ...

Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency … -
Y VANRENTERGHEM, P BARANY, JFE MANN, PG KERR, J … - Kidney International, 2002 - pt.wkhealth.com
... sub-groups (-0.05, -0.42, -0.31, respectively), demonstrating ... model of erythropoietin
therapy for uremic anemia. ... SOCIETY OF NEPHROLOGY, 2001, WEB SITE: http ...

Strong negative association between intake of tofu and anemia among Chinese adults in Jiangsu, China …
Z Shi, X Hu, B Yuan, X Pan, Y Dai, G Holmboe- … - J Am Diet Assoc, 2008 - ncbi.nlm.nih.gov
... may not work well with NCBI's Web applications. ... odds ratio for women was 0.31 (95%
confidence ... The association between tofu intake and anemia was independent of ...

PARASITEMIA, ANEMIA, AND MALARIAL ANEMIA IN INFANTS AND YOUNG CHILDREN IN A RURAL HOLOENDEMIC … -
JM ONG'ECHA, CC KELLER, TOM WERE, C OUMA, RO … - The American Journal of Tropical Medicine and Hygiene, 2006 - ASTMH
... on predisposition to malaria infection, screened windows were not protective versus
unscreened windows for parasitemia (P = 0.17), anemia (P = 0.31), or MA (P ...

… Between the TNF (-308) Promoter Polymorphism and Stroke Risk in Children With Sickle Cell Anemia -
C Hoppe, W Klitz, KD'Harlingue, S Cheng, M Grow, L … - Stroke, 2007 - Am Heart Assoc
... ahajournals.org located on the World Wide Web at: The ... The Stroke Prevention Trial
in Sickle Cell Anemia (STOP) Investigators ... 16 RR RG GG 0.39 15 (0.31) 24 10 ...

Anemia as a risk factor for infectious diseases in infants and toddlers: Results from a prospective … -
A Levy, D Fraser, SD Rosen, R Dagan, RJ Deckelbaum … - European Journal of Epidemiology, 2005 - Springer
... Thus this analysis attempted to disentangle the anemia infection causal web. ... Hb <
11.0 g/dl) and those without anemia (Hb ? 11.0 g ... 9.4 ? 6.1 10.1 ? 5.9 0.31 ...

[PDF] Protective effect of multimicronutrient supplementation against anemia among children, women, and …
DL de Roma?a, S Verona, OA Vivanco, R Gross - The 1998?2001 Peru Multimicronutrient Supplementation Study …, 2006 - unu.edu
... 052. 22 WHZ 0.32?0.87 a 0.53?0.82 b 0.35?0.89 a. 001 0.31?0.84 0.46?0.87. 02. ... Protective
effect against anemia ... S150 References 1. WHO nutrition web page. ...

… 1 1 This article has been selected for the open discussion forum on the STS Web Site: http://www. …
AF Rossi, HS Seiden, RP Gross, RB Griepp - The Annals of Thoracic Surgery, 1999 - Soc Thorac Surgeons
... for the open discussion forum on the STS Web Site: http ... No 45 VSD 1 Repair RA 0.28
0.4 0.31 Yes ... Because these factors are affected by anemia, sepsis, and oxygen ...
-

Undertreatment of Anemia in Patients with Chronic Kidney Disease in the United States: Analysis of … -
RS Rasu, HJ Manley, T Crawford, R Balkrishnan - Clinical Therapeutics, 2007 - Elsevier
... on the character- istics of patients being treated for CKD-associated anemia and
the ... and summary statistics for each year are available at the NAMCS Web site. ...
-

Source: Google Scholar
 
 

Reversing Anemia Can Threaten Kidney Patients

November 16, 2006 03:58:06 PM PST
By Serena Gordon
HealthDay Reporter

THURSDAY, Nov. 16 (HealthDay News) -- For kidney disease patients, using drugs to reverse anemia by boosting red blood cell counts past U.S. Food and Drug Administration-recommended levels may do more harm than good, two new studies warn.

In fact, one of the studies in this week's issue of the New England Journal of Medicine was stopped prematurely by its safety panel after researchers reported more deaths and complications in the high-hemoglobin group and little likelihood that the treatment would provide any patient benefit.

The findings prompted the FDA on Wednesday to say it would review data from the study -- called the CHOIR trial -- and revisit the question of exactly how much anemia correction is too much.

The outcome of the two NEJM trials is also stirring debate as to whether doctors are over-prescribing blockbuster anti-anemia drugs such as Amgen's Epogen and Johnson and Johnson's Procrit.

"Treatment of anemia is important, but care needs to be taken in how aggressively anemia is treated," said the lead author of the CHOIR trial, Dr. Ajay Singh, clinical chief of the renal division and director of dialysis at Brigham and Women's Hospital in Boston, Mass. "The current evidence suggests that too high a hemoglobin level may be associated with some risk."

Article continues below and (thank you)

 

Anemia is a common complication of kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). That's because normally functioning kidneys produce the hormone erythropoietin (EPO), which is essential to the production of red blood cells. Once kidney disease develops, the kidneys often can't produce enough EPO anymore. Without enough EPO, the body doesn't make enough red blood cells and anemia results.

Hemoglobin is a component of red blood cells and is responsible for carrying oxygen throughout the body. Normal hemoglobin levels are between 13 and 15 grams per deciliter. Without the right number of red blood cells and hemoglobin, the body's tissues don't get enough oxygen to function properly. Anemic people get tired more easily and may develop heart problems, according to the NIDDK.

In the past, blood transfusions were necessary to keep patients' levels of red blood cells and hemoglobin up to healthy levels. In the late 1980s, a synthetic version of erythropoietin called epoetin (brand names Epogen, Procrit) became available and made treating kidney disease-related anemia easier.

However, there has been uncertainty as to how close to normal blood levels hemoglobin should be targeted. Current recommendations from the National Kidney Foundation suggest that doctors try to maintain hemoglobin levels to at least 11, but not above 13 grams per deciliter.

In the first study, Singh and his colleagues recruited more than 1,400 people with chronic kidney disease from 130 centers across the United States. None of these patients yet needed dialysis.

Half of the group was targeted to achieve hemoglobin levels of 13.5 grams per deciliter, while the other half was targeted to achieve 11.3 grams per deciliter. The study lasted 16 months.

Those in the high-hemoglobin group had a 34 percent increased risk of having a serious complication, including death, congestive heart failure and stroke compared to those in the lower group. Quality-of-life improvements were similar in both groups.

The study was funded by drug makers Johnson and Johnson and Ortho Biotech, which together make Procrit.

In the second study, European researchers targeted hemoglobin levels to the normal range of 13 to 15 grams per deciliter for 226 people with chronic kidney disease. Another 250 were given enough epoetin to keep their hemoglobin levels between 10.5 and 11.5 grams per deciliter.

This study found no difference in cardiovascular outcomes, but did find that more people in the group targeted for higher hemoglobin levels ended up needing dialysis sooner. Quality-of-life improvements were greater in the high hemoglobin group in this study, which was funded by Hoffman-LaRoche, the maker of another epoetin drug, NeoRecormon.

In an accompanying editorial, Dr. Julie Ingelfinger and co-author Dr. Giuseppe Remuzzi cautioned doctors about overzealously raising kidney patients' red blood cell counts. They believe there may be several reasons why people with chronic kidney disease don't improve when hemoglobin levels are raised to normal.

"I think there are probably multiple reasons," said Ingelfinger, a professor of pediatrics at Harvard Medical School and a senior consultant in pediatric nephrology at Massachusetts General Hospital in Boston. "Many people think it's because you've got a group of people who have vascular disease that start to feel better and do more once they're treated, and then they may have cardiac events because they're doing more."

Dr. Robert Provenzano, chief of nephrology at St. John Hospital and Medical Center in Detroit said it's possible that "years of chronic kidney disease has caused so much damage that they can't tolerate higher hemoglobin." Provenzano was involved in Singh's study.

Others are concerned that Medicare rules governing kidney dialysis are boosting the use of anti-anemia drugs. According to the Boston Globe, Medicare currently covers most dialysis treatments. Under agency rules, dialysis clinics receive a 6 percent profit on their use of Amgen's Epogen. Critics say this encourages the hazardous overuse of the drug. Dr. Barry Straube, Medicare's chief medical officer, told the Globe that the agency would review the CHOIR study and see whether changes in its reimbursement policy are needed.

In a letter sent yesterday to Medicare, Congressman Bill Thomas (R-Calif.), chairman of the House Ways and Means Committee, and Pete Stark (D-Calif.), ranking member of the Ways and Means subcommittee on health, voiced their concern that Medicare is failing to "stem the systemic abuse of Epogen, resulting in costs to taxpayers and potential health dangers to patients," the Globe reported.

The CHOIR study results are also putting the new National Kidney Foundation guidelines -- developed with drug industry funding -- in the spotlight. In their editorial, Ingelfinger and Remuzzi note the recommendations "are not based on persuasive randomized, controlled trials." Speaking to the Globe, the foundation's vice president for scientific activities, Kerry Willis, said the group would look over the new findings to see if they warrant making changes in the recommendations.

But Ingelfinger also stressed that anti-anemia drugs have been a boon to kidney patients since their introduction two decades ago.

"It's important to remember what life was like before the possibility of transfusion-free correction of anemia," Ingelfinger said. "People felt terrible. Now we know that complete correction isn't needed, and these studies suggest that everybody should be vigilant to not overcorrect anemia."

More information

To learn more about anemia and kidney disease, visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.

 

EPA Phasing Out AZM Insecticide

The U.S. Environmental Protection Agency on Thursday announced its final decision to phase out the 10 remaining approved uses for the organophosphate insecticide azinphos-methyl (AZM) over the next five years.

The use of AZM on brussels sprouts and nursery stock will end in September 2007; on almonds, pistachios and walnuts by October 2009; and on apples, blueberries, cherries, parsley and pears by September 2012.

During the phase out period, the EPA said it is decreasing AZM application rates.

All other uses of the insecticide have been voluntarily discontinued by the registrants, the EPA said. In addition, AZM manufacturers have agreed to develop training materials to instruct farm workers and others on how to avoid unnecessary exposure.

-----

Brain Tumor Vaccine Shows Promise

A vaccine for glioma brain tumors is showing promising results, according to preliminary data from a clinical trial at the University of California, San Francisco Medical Center.

These early findings from the first group of six patients showed that the vaccine vitespen (trademark name Oncophage) was associated with tumor-specific immune responses in patients with recurrent, high-grade glioma.

The vaccine is derived from each patient's own tumor.

"This is the first documentation of a glioma-specific immune response after vaccination with vitespen," and further research is warranted, principal investigator Dr. Andrew T. Parsa, assistant professor in the department of neurological surgery, said in a prepared statement.

The findings were presented Thursday at a meeting of the Society of Neuro-Oncology.

-----

Virus Sickens 700 on Cruise Ship

A highly-contagious stomach virus sickened more than 700 passengers and crew during a trans-Atlantic cruise from Rome to Florida.

The Carnival Cruise Lines ship Liberty, carrying 2,804 passengers and 1,166 crew members, began its 16-day voyage on Nov. 3. Carnival officials said the number of new cases has dropped significantly in the last few days and the ship will complete its cruise, The New York Times reported.

"The majority of affected guests have already recovered," the cruise line said a statement. It offered a hint about a possible cause of the outbreak.

"After the start of the voyage, it was determined that at least two guests were sick with gastrointestinal illness just prior to the cruise and sought medical treatment in Rome before boarding the ship," Carnival said.

The U.S. Centers for Disease Control and Prevention will send three environmental health experts to the Liberty. The specialists will oversee cleaning of the ship and help pinpoint the outbreak's cause, The Times said.

-----

Bill Would Improve U.S. Drug Safety

U.S. lawmakers are being urged to support a bipartisan bill to improve drug safety, the Associated Press reported.

The bill's provisions include: a temporary ban on consumer advertising of drugs newly approved by the U.S. Food and Drug Administration; drug company-devised safety plans for new drugs; more disclosure of the results of human drug trials; and giving the FDA the power to order drugmakers to conduct safety studies of drugs after they're on the market.

The bill, which also calls for the drug industry to pay higher user fees to the FDA, was introduced in August by Senators Mike Enzi (R-Wyo.) and Ted Kennedy (D-Mass.) in the wake of a number of drug recalls and safety alerts.

Witnesses in Congressional hearings testified that the bill would improve safety and boost public confidence, the AP reported.

"The initiative now before you represents the best opportunity in many years to fix these chronic [drug safety] problems," Dr. Steve Nissen told lawmakers. Nissen was a member of an FDA advisory panel that in 2001 recommended new warnings be added to the now recalled painkiller Vioxx.

-----

Survey Queries Smokers on Why They Should Quit

Health concerns and the welfare of a child or grandchild are key motivators for people to quit smoking, says an American Cancer Society survey released Thursday.

The survey of 454 former smokers and 281 current smokers who have tried to quit at least once also cited not smelling like smoke as a key reason to kick the habit.

Among the survey's findings:

  • 86 percent of former smokers and 70 percent of current smokers cited health concerns as the most important reason for quitting, while 55 percent in each group said the welfare of a child or grandchild was the second most important reason.
  • More than a third of former smokers and 43 percent of current smokers said the cost of cigarettes also was a key reason to quit.
  • Respondents cited other reasons to stop smoking, including reducing the risk of cancer, feeling a sense of accomplishment, being able to exercise more, and improving relationships with family and friends.

The survey was released on the 30th anniversary of the Great American Smokeout, when people are encouraged to give up cigarettes for at least a day.

-----

Falls Leading Cause of Fatal Injuries Among Elderly

Fall-related deaths among people 65 and older in the United States rose by more than 55 percent from 1993 to 2003, says a report released Thursday in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report. Falls are now the leading cause of injury deaths for elderly Americans, the report said.

In 2003, more than 13,700 older adults died from falls, nearly 1.8 million seniors were treated in hospital emergency departments for nonfatal fall-related injuries, and more than 460,000 elderly people were hospitalized for injuries caused by falls.

The report also said that, in 2000, direct medical costs for falls among seniors totaled some $19 billion.

Between 1993 and 2003, fatal falls increased for all races and both sexes, but men were more likely than women to die from falls. Women, however, averaged 48 percent more non-fatal fall injuries than men.

-----

Wal-Mart Expands Discount Drug Program

Wal-Mart is adding 17 more medications to its list of $4 generic prescription drugs and is expanding the program to 502 more stores in 11 additional states, the Associated Press reported. Once implemented, the program will involve 3,009 stores in 38 states.

Consumers will be able to pay $4 for a 30-day supply of any of 331 drugs, the company said Thursday.

New states added to the program are: Idaho, Kentucky, Maine, Massachusetts, Nebraska, Oklahoma, Rhode Island, South Carolina, Utah, Washington, and West Virginia, the AP reported.

Wal-Mart started the discount generic drug program in Florida in September and had planned to expand it early next year. However, the company said it decided to move up its timetable and expand the program as soon as possible.

 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; Nedws9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 

 © 2002-2006

Keywords::

Contact Iconocast

Home Page